不同抗栓策略对冠心病合并房颤患者预后的影响:一项荟萃分析
该荟萃分析纳入12项随机对照试验共11 353例冠心病合并房颤患者,比较三联抗栓(阿司匹林+氯吡格雷+华法林)与双联抗血小板(阿司匹林+氯吡格雷)策略。结果显示两组MACE和缺血性卒中发生率无显著差异,但三联抗栓组主要出血事件风险约为双联组的2倍。
要点
- 三联抗栓与双联抗血小板相比,MACE和缺血性卒中风险无显著差异。
- 三联抗栓组主要出血事件发生率显著高于双联抗血小板组(OR=1.94)。
- 冠心病合并房颤患者抗栓策略需权衡缺血与出血风险。
核心结论
- 冠心病合并房颤患者三联抗栓治疗与双联抗血小板治疗相比,缺血性卒中风险相似,但主要出血事件风险更高。
研究设计与样本
- 荟萃分析,检索Embase、Pubmed、Cochrane Central Register of Controlled Trials、Medline、CBM、中国知网、万方等数据库及会议论文集,截止2016年4月30日,纳入12项随机对照试验共11 353例患者。
主要发现
- 三联抗栓组3 486例,双联抗血小板组7 867例。
- MACE发生率两组差异无统计学意义(OR=0.93,95%CI 0.74-1.18,P>0.05)。
- 缺血性卒中发生率两组差异无统计学意义(OR=0.88,95%CI 0.70-1.10,P=0.27)。
- 主要出血事件发生率三联抗栓组显著高于双联抗血小板组(OR=1.94,95%CI 1.33-2.82,P=0.000 6)。
临床怎么用
- 对于冠心病合并房颤患者,选择三联抗栓策略时应充分评估出血风险,警惕主要出血事件增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the impact of various anticoagulation antiplatelet therapy strategies on the prognosis of patients with coronary heart disease combining with atrial fibrillation. Methods: Present meta analysis was performed according to search results on English EMBASE database by computer retrieval, Pubmed, the Cochrane Central Register of Controlled Trials, Medline, Chinese CBM database, CNKI database, Wan Fang database, China science and technology papers online electronic databases, manual retrieval for important international conference proceedings up to April 30 2016. Trials published in English and Chinese language, which met the Cochrane system evaluation requirements were included and the inclusion and exclusion criteria were made based on Cochrane system evaluation requirements. The end point is the incident of major adverse cardiac events (MACE), ischemic stroke and major bleeding events. The patients were randomly assigned into triple antithrombotic therapy (aspirin+ clopidogrel+ warfarin) group and dual antiplatelet therapy (aspirin+ clopidogrel) group.The collected full-text literatures underwent further quality assessment of the risks of bias using RevMan 5.3 software. Impact of various antithrombotic therapeutic strategies on the outcome of coronary heart disease patients combining with atrial fibrillation were evaluated. Results: In this meta analysis, 12 randomized controlled trials with 11 353 patients were included. Among these patients, 3 486 patients received triple antithrombotic therapy and 7 867 patients received dual anti-platelet therapy. There was no significant difference in incidence rate of MACE (OR=0.93, 95%CI 0.74-1.18, P>0.05) and the incidence rate of ischemic stroke (OR=0.88, 95%CI 0.70-1.10, P=0.27) between the two patients groups. However, the incidence rate of major bleeding events in triple antithrombotic therapy group was twice higher than that in dual anti-platelet therapy (OR=1.94, 95%CI 1.33-2.82, P=0.000 6). Conclusion: Compared with dual anti-platelet therapy strategy, coronary heart disease patients combining with atrial fibrillation who were treated by triple antithrombotic therapy strategy have the similar outcome on risk of ischemic stroke, but higher risk of major bleeding events. 目的: 比较冠心病合并心房颤动(房颤)患者经皮冠状动脉介入治疗(PCI)术后三联抗栓治疗与双联抗血小板治疗策略对预后的影响。 方法: 本研究为荟萃分析。通过计算机检索英文数据库Embase、Pubmed、Cochrane Central Register of Controlled Trials、Medline,中文数据库CBM、中国知网数据库、万方数据库、中国科技论文等在线电子数据库,手工检索国际上重要会议论文集,检索截止时间为2016年4月30日,语言选择英文和中文。按照Cochrane系统评价要求制定纳入、排除标准。主要研究终点为主要不良心血管事件(MACE)、缺血性卒中和主要出血事件。将纳入的患者分为三联(阿司匹林+氯吡格雷+华法林)抗栓治疗组和双联(阿司匹林+氯吡格雷)抗血小板治疗组。根据标准制定检索策略,提取文献资料。运用RevMan 5.3软件对文献质量偏倚风险进行评估,比较冠心病合并房颤患者PCI术后三联抗栓治疗与双联抗血小板治疗MACE、缺血性卒中和主要出血事件的发生率。 结果: 共纳入随机对照试验12项,包含患者11 353例,其中三联抗栓治疗组3 486例,双联抗血小板治疗组7 867例。分析发现,两组间MACE和缺血性卒中发生率差异均无统计学意义(MACE:OR=0.93,95%CI 0.74~1.18,P>0.05;缺血性卒中:OR=0.88,95%CI 0.70~1.10,P=0.27),但三联抗栓治疗组患者主要出血事件的发生率明显高于双联抗血小板治疗组(OR=1.94,95%CI 1.33~2.82,P=0.000 6)。 结论: 冠心病合并房颤患者PCI术后三联抗栓治疗与双联抗血小板治疗策略远期疗效相当,但出血风险较高。.
引用
- Yuan C, Zhong L, Huang RC, et al. [Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis]. Zhonghua Xin Xue Guan Bing Za Zhi. 2017. PMID: 28648031. doi:10.3760/cma.j.issn.0253-3758.2017.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。